Skip to main content

Advertisement

Table 5 Extent of exposure and tolerability assessments, treated set

From: Treatment of acute rhinitis with a nasal spray containing tramazoline and essential oils: a multicenter, uncontrolled, observational trial

  Children Adolescents Adults Total
Patients, N (%) 108 (36.0) 30 (10.0) 162 (54.0) 300 (100)
Exposure to trial medication
 Mean days of exposure to trial drug (SD) 7.1 (1.3) 6.8 (1.4) 7.2 (1.8) 7.1 (1.6)
 Median days of exposure to trial drug 7 6 7 7
 Minimum 4 5 3 3
 Maximum 10 9 12 12
Patients’ tolerability assessment, N (%)
 Very good 100 (92.6) 25 (83.3) 105 (64.8) 236 (78.7)
 Good 7 (6.5) 5 (16.7) 50 (30.9) 64 (21.3)
 Fair 1 (0.9) 0 (0.0) 6 (3.7) 7 (2.3)
 Poor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Investigators’ tolerability assessment, N (%)
 Very good 101 (93.6) 26 (86.7) 109 (67.3) 236 (78.7)
 Good 7 (6.5) 4 (13.3) 53 (32.7) 64 (21.3)
 Fair 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Poor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)